Of clinical relevance, oBHV has a particular affinity for cancers with a high incidence of mutant KRAS [22], a negative therapeutic outcome predictor of hard-to-treat cancers such as lung, colorectal and pancreatic cancers. The gene discussed is KRAS; the disease is cancer.